Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03045341 · ClinicalTrials.gov registry record · Phase 2
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
A Phase 2 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT03045341: Completed Phase 2 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
NCT03045341 is a Phase 2 study of Obesity and Binge-Eating Disorder that has completed, run by Yale University. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03045341, a Phase 2 study of Obesity and Binge-Eating Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.
Primary Outcome
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency will be defined continuously (analyzed dimensionally).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NB medication (Naltrexone Bupropion combination)
- BEHAVIORAL Behavioral Weight Loss (BWL) counseling
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
What the finished NCT03045341 record still lists
NCT03045341 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03045341 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03045341 about?
NCT03045341 is a clinical study titled "Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment". This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltr...
What is the current status of trial NCT03045341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2017-02-27. Estimated completion is 2022-12-16.
What conditions does trial NCT03045341 study?
This clinical trial studies the following conditions: Obesity, Binge-Eating Disorder.
What interventions are being tested in trial NCT03045341?
The interventions under investigation include: Placebo (OTHER), NB medication (Naltrexone Bupropion combination) (DRUG), Behavioral Weight Loss (BWL) counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT03045341?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03045341 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03045341's enrollment target sits among peer trials
136 407th of 1053 higher than 641 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI